Skip to content
Home
Wins
Flops
Big movers
Daily roundups
Idiopathic Hypersomnia trial results
Search drug, company, condition, ticker or NCT ID
Search
Outcome
Any outcome
Wins (met endpoint / approved)
Flops (missed / terminated / rejected)
Met endpoint
Missed endpoint
Terminated / discontinued
Mixed results
Trial update
Approved
Rejected (CRL)
Phase
Any phase
Phase 1
Phase 1/2
Phase 2 (12)
Phase 2/3 (1)
Phase 3 (13)
Phase 4
Condition
Any condition
Alcohol Use Disorder (AUD) (1)
Androgenetic Alopecia (1)
Atopic Dermatitis (1)
Autism Spectrum Disorder (1)
Bipolar 1 Disorder (1)
Chronic Spontaneous Urticaria (1)
Duchenne Muscular Dystrophy (1)
Generalized Anxiety Disorder (2)
Hidradenitis Suppurativa (1)
Idiopathic Hypersomnia (1)
Metastatic Non-Small Cell Lung Cancer (1)
Mycobacterium Infections, Nontuberculous (1)
Plaque Psoriasis (1)
Pneumococcal Disease (1)
Polycythemia Vera (1)
Post Bariatric Hypoglycemia (1)
Pulmonary Hypertension (2)
Recurrent IDH1-Mutant High-Grade Glioma (1)
Relapsed Diffuse Large B-Cell Lymphoma (1)
Relapsing Forms of Multiple Sclerosis (1)
Schizophrenia (2)
SLE (1)
Wet Age-related Macular Degeneration (1)
Company
Any company
ADC Therapeutics (1)
Alkermes plc. (1)
Altimmune (1)
Alto Neuroscience (1)
Alumis (1)
Amylyx Pharmaceuticals (1)
Apogee Therapeutics (1)
ArriVent (1)
Avalo Therapeutics (1)
Celldex (1)
Definium Therapeutics (2)
Insmed (1)
Kodiak Sciences (1)
MapLight (1)
MapLight Therapeutics (1)
NeOnc Technologies (1)
Oruka Therapeutics (1)
Rapport Therapeutics (1)
REGENXBIO (1)
Roivant (1)
Silence Therapeutics (1)
Tenax Therapeutics (1)
TG Therapeutics (1)
Vaxcyte (1)
Veradermics (1)
Company type
All companies
Public companies only
Patients
Any size
Under 100 patients
100–499 patients
500+ patients
Stock move (24h)
Any move
Big movers (±10%+)
Up 10% or more
Down 10% or more
Any rise
Any fall
24h price pending
Private / not listed
Announced
Any time
Today
Last 7 days
Last 30 days
Apply filters
Clear all
Quick
Wins
Flops
Big movers
Today
Phase 3 flops
Phases
Phase 1
Phase 1/2
Phase 2
12
Phase 2/3
1
Phase 3
13
Phase 4
Top conditions
Schizophrenia
2
Pulmonary Hypertension
2
Generalized Anxiety Disorder
2
Mycobacterium Infections, Nontuberculous
1
Autism Spectrum Disorder
1
Relapsed Diffuse Large B-Cell Lymphoma
1
Atopic Dermatitis
1
Idiopathic Hypersomnia
1
Hidradenitis Suppurativa
1
Duchenne Muscular Dystrophy
1
1 result
Idiopathic Hypersomnia
×
Met endpoint
May 12, 2026
LUMRYZ
Phase 3
Idiopathic Hypersomnia
Alkermes plc.
ALKS
24h stock move
▲
+7.13%
